QDEL logo

QUIDELORTHO CORP

QDELNASDAQ
πŸ† #2706 by market capUS Equity
$952.40β–Ό $18.19 (βˆ’1.91%)
Simulated price
πŸ””
Track QDEL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.9%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$727M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-2.5%
Declining
πŸ“ŠGross Margin
44.6%
Healthy
πŸ’΅FCF Margin
3.6%
Moderate
βš–οΈP/S Ratio
0.3x
Cheap
Otter Score
76
Good
No chart data available for QDEL.

Trading Snapshot

Day Range
$943.14 – $962.55
52-Week Range
$9.92 – $35.58
Volume
$5.95B
Avg Volume
$7.51B
Shares Outstanding
68.2M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$2.73B
Last Q Revenue
$631M
P/E Ratio
β€”
P/S Ratio
0.3x
EPS (TTM)
$-15.40
Dividend Yield
β€”
Dilution (1yr)
+0.9%

Why Investors Own QDEL

  • βœ“High-growth profile β€” revenue up +36.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

QDEL logo

QUIDELORTHO CORP

QDEL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.7Bβ–Ό βˆ’1.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
46.7%β–² +1.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$919Mβ–Ό βˆ’53.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$83Mβ–Ό βˆ’26.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
67.8Mβ–² +0.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.7Bβ–Ό βˆ’$81M YoY
StockOtter Β· stockotter.space

About QUIDELORTHO CORP

QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$1,102.00
β–² +15.7% Upside
High Target$1,323.85
Low Target$826.97
Based on 11 analysts

Latest News & Updates